Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mind Medicine Mindmed Inc (MNMD)

Mind Medicine Mindmed Inc (MNMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 941,523
  • Shares Outstanding, K 306,685
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,340 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.13
Trade MNMD with:

Options Overview

Details
  • Implied Volatility 94.04%
  • Historical Volatility 51.97%
  • IV Percentile 4%
  • IV Rank 9.48%
  • IV High 185.97% on 05/20/21
  • IV Low 84.42% on 07/22/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4,486
  • Volume Avg (30-Day) 9,715
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 157,899
  • Open Int (30-Day) 183,278

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +2.33%
on 07/19/21
3.92 -21.68%
on 06/28/21
-0.40 (-11.53%)
since 06/23/21
3-Month
2.85 +7.72%
on 05/11/21
5.77 -46.79%
on 04/27/21
-0.45 (-12.78%)
since 04/23/21
52-Week
0.30 +923.33%
on 07/27/20
5.77 -46.79%
on 04/27/21
+2.75 (+871.52%)
since 07/23/20

Most Recent Stories

More News
This Drug Could Soon Help Millions Battling the Obesity Epidemic

The obesity epidemic in the U.S. is only getting worse. In fact, by the time 2030 rolls around, nearly ...

NMDBF : 0.1093 (-8.84%)
ATAI : 17.38 (+0.70%)
MNMD : 3.07 (-2.23%)
COPHF : 0.0910 (-7.14%)
PHRRF : 0.8600 (+6.46%)
PHRM.CN : 1.090 (+5.83%)
NEON.CN : 0.140 (-6.67%)
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

/PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics...

LKYSF : 0.7600 (-2.56%)
SEEL : 2.33 (-4.90%)
NUMI.VN : 0.950 (-3.06%)
MNMD : 3.07 (-2.23%)
MYCOF : 0.3759 (-4.88%)
TRYP.CN : 0.540 (+3.85%)
TRYPF : 0.4200 (+3.58%)
3 Pyschedelic Stocks That Investors Should Keep on Their Radars

ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on...

ATAI : 17.38 (+0.70%)
CMPS : 36.83 (-0.19%)
MNMD : 3.07 (-2.23%)
Psychedelic Decriminalization Creating Market Opportunities

/PRNewswire/ --What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Legalization efforts began with ...

MNMD : 3.07 (-2.23%)
CMPS : 36.83 (-0.19%)
ATAI : 17.38 (+0.70%)
NUMI.VN : 0.950 (-3.06%)
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

/PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, , will be...

MNMD : 3.07 (-2.23%)
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

/PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. (""), a leader in helping healthcare organizations safely...

MNMD : 3.07 (-2.23%)
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market

/PRNewswire/ -- Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of chemical substances...

OPTI.CN : 0.720 (+2.86%)
OPTHF : 0.5758 (-0.72%)
MNMD : 3.07 (-2.23%)
CMPS : 36.83 (-0.19%)
ATAI : 17.38 (+0.70%)
CLXPF : 3.0000 (+1.01%)
GTMS.TO : 14.88 (-2.43%)
GBNH : 11.89 (-1.77%)
This Key Psychedelic Could Revolutionize Depression Treatment for Millions

Mental health is on the decline all over the world. At the moment, nearly 264 million people are ...

CLXPF : 3.0000 (+1.01%)
MNMD : 3.07 (-2.23%)
NMED : 0.0001 (unch)
CMPS : 36.83 (-0.19%)
FTRPF : 6.0050 (+1.61%)
FTRP.CN : 5.550 (+1.46%)
MYND.CN : 0.930 (-19.13%)
GW Pharma Sells for Billions; Psychedelic Company Following Similar Path

/PRNewswire/ -- In ,  listed on Nasdaq, selling 3.5 million shares at each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds....

ATAI : 17.38 (+0.70%)
TRYP.CN : 0.540 (+3.85%)
TRYPF : 0.4200 (+3.58%)
CMPS : 36.83 (-0.19%)
MNMD : 3.07 (-2.23%)
JAZZ : 173.93 (+0.06%)
MindMed Included in FTSE Russell 3000® Index

/PRNewswire/ -- MindMed a leading psychedelic-inspired medicine company announced that effective , MindMed has been added to the FTSE Russell 3000 index which measures the performance of the largest 3,000...

MNMD : 3.07 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 3.23
2nd Resistance Point 3.18
1st Resistance Point 3.13
Last Price 3.07
1st Support Level 3.03
2nd Support Level 2.98
3rd Support Level 2.93

See More

52-Week High 5.77
Fibonacci 61.8% 3.68
Last Price 3.07
Fibonacci 50% 3.04
Fibonacci 38.2% 2.39
52-Week Low 0.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar